Thomas Michaels is an Assistant Professor at the Department of Biology, ETH Zürich, leading the Michaels Group . His research focuses on theoretical models of biomolecular condensates and protein aggregation in biological systems. Research Themes : Protein aggregation, liquid-liquid phase separation, membrane biophysics, and the role of condensates in neurodegenerative diseases like Alzheimer’s and Parkinson’s. Collaborative Approach : Integrates theoretical physics, control theory, and computational biology with experimental validation to design therapeutic strategies. Recent Publications highlight his work on amyloid formation mechanisms, lipid interactions, and phase-separated compartments as biochemical reactors. His group trains PhD students in systems biology and biocondensate physics.
David Vocadlo is a Distinguished Professor of Chemistry and Molecular Biology & Biochemistry at Simon Fraser University (SFU), holding the Canada Research Chair in Chemical Biology. His research focuses on Chemical Glycobiology, investigating carbohydrate-processing enzymes and developing chemical tools to study glycan roles in health and disease. His lab explores O-GlcNAc signaling, neurodegenerative disorders (e.g., Alzheimer’s, Parkinson’s), and enzyme inhibitors for therapeutic applications. Education: PhD from University of British Columbia (UBC), followed by a CIHR postdoctoral fellowship at UC Berkeley. Key roles include E.W.R. Steacie Memorial Fellow and Royal Society Fellow. Research highlights include O-GlcNAcase inhibitors for neuroprotection, glycan structure-function relationships, and enzyme activity imaging tools. Collaborates globally with experts in glycobiology and employs cutting-edge techniques like chemical synthesis, mass spectrometry, and live-cell imaging. Awards: Distinguished Professor title, Canada Research Chair, Royal Society Fellowship. Active in training researchers through SFU’s graduate programs, emphasizing interdisciplinary approaches. Lab members work on topics ranging from enzyme mechanisms to disease modeling.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Masato Kato serves as Professor in the Department of Biochemistry at the University of Texas Southwestern Medical Center since 2020 and concurrently as Team Leader at Japan's National Institutes for Quantum and Radiological Science and Technology. His academic trajectory includes progressive appointments from Assistant Professor (2004-2014) to Associate Professor (2014-2020) at UT Southwestern, with prior postdoctoral training at Harvard Medical School and Nara Institute of Science and Technology. 2020-present: Professor, Department of Biochemistry, UT Southwestern 2020-present: Team Leader, National Institutes for Quantum and Radiological Science and Technology, Japan 2014-2020: Associate Professor, Department of Biochemistry, UT Southwestern 2010-2014: Assistant Professor, Department of Biochemistry and Internal Medicine, UT Southwestern 2004-2010: Assistant Professor, Department of Internal Medicine, UT Southwestern 1999-2004: Postdoctoral Fellow, Ellenberger Lab, Harvard Medical School 1998-1999: Postdoctoral Fellow, Hakoshima Lab, Nara Institute of Science and Technology Dr. Kato's research pioneers the biophysical characterization of protein phase separation, particularly focusing on low-complexity domains (LCDs) in neurodegenerative disease contexts. His work establishes fundamental mechanisms of biomolecular condensate formation, including hydrogel polymerization, liquid-solid transitions, and mutation-induced dysregulation in ALS/FTD. Key contributions demonstrate how C9orf72-encoded poly-dipeptides disrupt nucleocytoplasmic transport and how redox states regulate Ataxin-2 phase behavior, bridging structural biochemistry with pathological mechanisms. Analysis of his 22 publications reveals a cohesive research program centered on LCD-driven phase transitions. The most recent 15 articles (2012-2019) systematically investigate pathological aggregation in neurodegeneration, structural basis of condensate formation, and regulatory mechanisms like phosphorylation and oxidation. This body of work establishes LCDs as central players in both physiological RNA granule assembly and disease-associated solidification, with strong emphasis on C9orf72-related ALS/FTD mechanisms. Dr. Kato maintains active leadership within the McKnight Laboratory at UT Southwestern, where his team employs integrated approaches spanning structural biology, cell biology, and biophysics to dissect phase separation mechanisms. His collaborative network includes prominent neuroscience and biochemistry groups, with co-authorship on key studies in Cell, Science, and PNAS.
Anthony D. Wagner is the Lucie Stern Professor in the Department of Psychology at Stanford University and Deputy Director of the Wu Tsai Neurosciences Institute. He holds affiliations with Stanford's Center for Cognitive and Neurobiological Imaging, Symbolic Systems Program, Human Biology Program, and Stanford Center on Longevity. His PhD (1997) is from Stanford University in Psychology. Research focuses on the neurobiology of learning, memory, and executive function across ages, with translational studies on aging, Alzheimer’s disease, multitasking, and neuroscience applications in law. Key themes include biomarker development for neurodegeneration, cognitive resilience, and the impact of attention on memory. Labs/teams include collaborations at the Wu Tsai Institute and neuroimaging centers. Recent work emphasizes tau PET imaging, proteomics of aging, and fluid biomarkers for Alzheimer’s prediction. He also explores societal impacts of neurotechnology and media on cognition.
Celeste Sagui is a Professor in the Department of Physics at North Carolina State University (NC State), affiliated with the College of Sciences. She holds additional roles as a faculty affiliate in Genomics Sciences at NC State and is a member of the Center for High Performance Simulation. Her research focuses on computational biophysics, biomolecular simulations, and free energy methods applied to nucleic acid structures, protein dynamics, and nanotechnology systems. She has contributed to the AMBER simulation package development, co-authoring versions from 10 to 14. Education: Doctorate in Physics, University of Toronto (1995) Licentiate degree, National University of San Luis, Argentina Research Interests: Sagui’s work explores DNA/RNA structure and phase transitions, electrostatic interactions, and methodologies for large-scale molecular simulations. Recent studies include nucleic acid hairpin instabilities linked to neurodegenerative diseases, polyglutamine aggregation mechanisms, and novel DNA motifs like the eGZ structure in Z-DNA. She employs quantum chemistry, density functional theory, and phase-field models to investigate systems ranging from biomolecules to nanomaterials. Publications: Her recent work emphasizes nucleic acid dynamics, free energy landscapes, and computational methods for studying diseases such as Friedreich’s ataxia and polyglutamine disorders. Key contributions include advancements in laser-driven simulations and infrared spectroscopy analysis of protein structures. Labs/Teams: Active in the Center for High Performance Simulation, focusing on high-throughput computational modeling and collaborative software development for biomolecular research.
Hang Lu is an Associate Professor in the Department of Communication and Media at the University of Michigan's College of Literature, Science, and the Arts. He specializes in science, health, environmental, and risk communication (ComSHER), with a focus on media psychology. His research explores audience responses to media messages about sensitive topics and strategies to enhance message effectiveness. Lu holds a Ph.D. in Communication from Cornell University (2018), along with advanced degrees from Cornell, Marquette University, and Central South University in China. He directs the Media and Risk (MaR) Lab and previously served as a postdoctoral fellow at the Annenberg Public Policy Center. His research spans four main areas: 1) emotion dynamics in media responses, 2) predictors of information behaviors, 3) media effects on stigmatization, and 4) AI applications in sensitive domains. He has published in journals like Journal of Communication , Risk Analysis , and Public Understanding of Science , earning multiple top paper awards. As Vice Chair of the Environmental Communication Division at the International Communication Association, Lu contributes to interdisciplinary dialogue. His work addresses critical societal issues such as climate change communication, vaccination hesitancy, and emerging technology ethics.
Prof. Ilse Dewachter is the head of the Biomed Neuroscience research group at Hasselt University (UHasselt), specializing in Alzheimer’s therapy and prevention for over 25 years. Her work focuses on multi-targeted therapies targeting tau, inflammation, and ApoE, alongside pioneering research into disease prevention via blood-based biomarkers. Recent studies explore a protective APOE3ch mutation that halted Alzheimer’s progression in a patient, offering hope for new treatments. Research Interests: - Alzheimer’s disease mechanisms (Abeta, tau, inflammation) - Multi-target therapies and biomarker development - Neurodegenerative disease prevention strategies - Genetic mutations impacting disease progression Articles Overview: Her most recent work (2025-2022) addresses neuroinflammation, tau propagation models, and AI-driven neuroimaging. Key themes include APOE genetics, blood-brain barrier dynamics, and exercise impacts on cognition. Funding & Grants: Current projects require significant investment for advanced biomarker equipment and clinical trials. A notable €300,000 grant funded research on brain lipid metabolism’s role in Alzheimer’s. Labs & Teams: Leads the BIOMED Neuroscience group at UHasselt, collaborating internationally on preclinical models and drug development.
James Shorter is a Professor of Biochemistry and Biophysics at the Perelman School of Medicine, University of Pennsylvania. He is affiliated with multiple prestigious institutes, including the Institute on Aging (IOA), the Institute for Translational Medicine and Therapeutics (ITMAT), the Penn Center for AIDS Research (CFAR), the Chemistry-Biology Interface (CBI), and the Penn Institute for RNA Innovation. He mentors several training programs such as the Penn Summer Undergraduate Internship Program (SUIP), PennPREP, and the Translational Research Immersion Program (TRIP), and serves as a Primary Trainer at the Center for Neurodegenerative Research (CNDR). Ph.D. in Cell Biology, University of London, 2000 M.A. in Biology, University of Oxford, 1995 Dr. Shorter’s research focuses on protein homeostasis, particularly the mechanisms of protein disaggregation and the role of prion-like domains in neurodegenerative diseases such as ALS, Alzheimer’s, Parkinson’s, and frontotemporal lobar degeneration. His lab investigates the Hsp104 disaggregase from yeast and has engineered variants to combat human proteinopathies. They also identified the mammalian disaggregase system (Hsp110/Hsp70/Hsp40) and explore how small molecules and nuclear import receptors can reverse pathological phase transitions of RNA-binding proteins like TDP-43 and FUS. His work bridges structural biology, genetics, and translational neuroscience. His recent publications highlight trends in targeting TDP-43 and FUS proteinopathies, engineering Hsp104 for selective detoxification, understanding mitochondrial disaggregases like Skd3, and modulating phase transitions with nuclear import receptors. His research spans from fundamental mechanisms of protein folding to therapeutic development for neurodegenerative diseases. Faculty Member, Institute on Aging (IOA) Faculty Member, Institute for Translational Medicine and Therapeutics (ITMAT) Mentor, Penn Summer Undergraduate Internship Program (SUIP) Primary Trainer, Center for Neurodegenerative Research (CNDR) Faculty Member, Penn Center for AIDS Research (CFAR) Member, Penn Institute for RNA Innovation Mentor, Translational Research Immersion Program (TRIP) Dr. Shorter advises numerous graduate students and postdoctoral researchers through the Biochemistry and Molecular Biophysics, Pharmacology, Neuroscience, and Cell and Molecular Biology graduate groups. His lab receives funding from NIH and other sources to support research on protein disaggregation, phase separation, and neurodegenerative disease mechanisms. He has trained many scientists now active in academia and biotech. His lab, located in Stellar-Chance Laboratories, operates at the intersection of biochemistry, cell biology, and translational medicine, with active projects on Hsp104 engineering, mitochondrial proteostasis, and the role of RNA-binding proteins in disease. The lab collaborates widely across Penn and with international partners to advance understanding and treatment of protein misfolding disorders.
Chris B. Schaffer is a Professor in the Meinig School of Biomedical Engineering at Cornell University, specializing in developing advanced optical techniques to study neurovascular dynamics in neurological diseases. His lab focuses on Alzheimer’s disease mechanisms, leveraging multiphoton microscopy and in vivo imaging to explore capillary stalling, cerebral blood flow deficits, and their cognitive impacts. He holds a Ph.D. in Physics from Harvard University and postdoctoral training in neuroscience at UC San Diego. Research interests include biomedical imaging instrumentation, neurodegenerative disease modeling, and science education innovation. Awards include AAAS Fellowship (2021), AIMBE Fellowship (2019), and multiple teaching accolades. His work bridges engineering and medicine, with contributions to spinal cord injury studies, epilepsy, and vascular contributions to dementia (VCID). Notable discoveries include identifying neutrophil-induced capillary stalls as a key Alzheimer’s disease mechanism and demonstrating cerebral blood flow improvements can restore memory in mouse models. His lab also develops educational tools emphasizing science as a discovery process, used in K-12 and university settings.
Denise Head is Professor of Psychological & Brain Sciences and Associate Chair at Washington University in St. Louis, with an additional appointment as Associate Professor in Radiology. Her research integrates cognitive neuroscience and neuroimaging to study cognitive aging and Alzheimer's disease. PhD, University of Memphis MS, University of Memphis BS, University of New Orleans Her research focuses on age-related cognitive changes and their neural underpinnings. Key areas include spatial navigation deficits in aging, the role of lifestyle factors (exercise, sleep, stress) in brain aging, and interventions to support cognitive function in older adults. She uses virtual reality, mobile eye-tracking, and neuroimaging techniques such as fMRI and DTI. The recent publications highlight a consistent trajectory in cognitive neuroscience and aging research, with emphasis on neuroimaging biomarkers, structural brain changes, and cognitive performance in normal and pathological aging. Her work bridges psychology, neurology, and radiology, contributing to early detection and understanding of Alzheimer's disease. Scientific Awards: No awards listed in the provided text. Dr. Head advises graduate students and leads a research lab focused on cognitive aging, though specific student names are not listed. Her lab investigates mediators of brain aging and develops methods to support spatial navigation in older adults. While specific grants are not mentioned, her ongoing research and recent publications suggest active external funding. She leads a research team in the Department of Psychological & Brain Sciences, utilizing advanced neuroimaging and behavioral methods to study aging and dementia. The lab integrates real-world and virtual experimental designs to understand spatial cognition and brain health in older populations.
Professor Richard Wade-Martins is a leading academic in University of Oxford 's Department of Physiology, Anatomy and Genetics . He directs the Molecular Neurodegeneration Research Laboratory and the Oxford Parkinson’s Disease Centre (OPDC). With degrees from Cambridge (MA) and Oxford (DPhil), he has held prestigious fellowships including Wellcome Trust Research Career Development Fellowship and NIH reviewer roles. His research targets molecular mechanisms in Parkinson’s and Alzheimer’s diseases through iPSC models , transgenic mice , and lysosomal function studies . He pioneered work on SNCA , MAPT , and LRRK2 gene pathways. Current projects focus on gene therapy and mitochondrial dysfunction in neurodegeneration. Key publications (2019–2025) reveal trends in single-cell transcriptomics , calcium channel inhibition , and TFEB/TFE3 lysosome modulation . His awards include Wellcome Trust Fellowships and advisory roles for Parkinson's UK , Alzheimer's Research UK , and EU consortia like StemBANCC and EFACTS . He leads the UK Dementia Platform iPSC Initiative and serves on international boards in Luxembourg and Canada.
Zhi-Pei Liang is the Franklin W. Woeltge Professor in the Department of Electrical and Computer Engineering at the University of Illinois at Urbana-Champaign, with joint appointments in the Department of Bioengineering, Beckman Institute for Advanced Science and Technology, and Coordinated Science Laboratory. His research spans biomedical engineering, medical imaging, and signal processing with a focus on advancing magnetic resonance imaging and spectroscopy technologies. His educational background includes a Ph.D. in Biomedical Engineering from Case Western Reserve University (1989) and a B.S. in Electrical Engineering from South-China University of Technology (1982), followed by postdoctoral training at UIUC (1989-1991). Professor Liang's research interests center on magnetic resonance imaging and spectroscopy , with particular emphasis on ultrafast imaging techniques , model-based reconstruction methods , and the integration of physics-based modeling with machine learning . His pioneering work on SPICE (SPectroscopic Imaging by exploiting spatiospectral CorrElation) has revolutionized high-resolution metabolic brain imaging by enabling label-free molecular imaging through the marriage of spin physics and machine learning. His research spans pattern recognition, parameter estimation, image formation theory, and algorithms for medical imaging applications. Analysis of his recent publications reveals a strong focus on high-resolution metabolic imaging , particularly using SPICE methodology to map brain metabolism with unprecedented detail. His work bridges fundamental physics of magnetic resonance with advanced computational methods to overcome traditional limitations in imaging speed and resolution. Current research directions include J-resolved spectroscopic imaging, deuterium-based metabolic mapping, and multimodal integration of PET and MRSI for studying neurological disorders. Elected to International Academy of Medical and Biological Engineering (2012) Gold Medal, International Society for Magnetic Resonance in Medicine (2022) Technical Achievement Award, IEEE Engineering in Medicine and Biology Society (2014) Fellow, National Academy of Inventors (2021) Author of influential book 'Principles of Magnetic Resonance Imaging' (1999) President of IEEE Engineering in Medicine and Biology Society (2011-2012) Professor Liang has advised numerous students and postdocs in biomedical imaging research and has received multiple teaching honors including the Ronald W. Pratt Outstanding Teaching Award (2005) and multiple listings among UIUC's Excellent Teachers. His research has been supported by various grants from NIH, NSF, and other funding agencies. He leads the SPICE (Spectroscopic Imaging by exploiting spatiospectral Correlation) research group which focuses on developing novel imaging techniques that combine physics-based modeling with machine learning for ultrafast metabolic imaging. His laboratory, part of the Beckman Institute's Integrative Imaging Theme, collaborates extensively with clinical researchers at Carle Illinois College of Medicine and other institutions to translate advanced imaging techniques into clinical applications for neurological disorders, cancer, and metabolic diseases. Current projects focus on high-resolution mapping of brain metabolism in Alzheimer's disease, stroke, and brain tumors using novel MR spectroscopic imaging techniques.
Hideyuki Takahashi is an Associate Research Scientist in the Department of Neuroscience at Yale University School of Medicine. He holds a PhD from Waseda University (2005) and has established himself as a prominent researcher in neurodegenerative diseases, particularly focusing on lysosomal biology and protein aggregation mechanisms. Dr. Takahashi's research primarily investigates the role of progranulin, TMEM106B, and other molecular players in neurodegenerative conditions including Alzheimer's disease, frontotemporal dementia, and tauopathies. His work spans multiple approaches from molecular and cellular neuroscience to animal models of disease. His recent publications demonstrate a strong focus on lysosomal dysfunction in neurodegeneration, with particular attention to how TMEM106B interacts with other proteins to influence disease progression. The research trends show increasing emphasis on therapeutic interventions targeting specific molecular pathways involved in protein aggregation and synaptic loss. ORCID: 0009-0004-4969-977X Dr. Takahashi maintains active collaborations with several leading researchers at Yale, most notably with Stephen Strittmatter (with whom he has 16 common publications), as well as Anita Huttner, Anthony Koleske, and Le Zhang. His research program appears well-integrated within Yale's neuroscience community, contributing significantly to our understanding of neurodegenerative disease mechanisms.
Federica Agosta is an Associate Professor of Neurology at Vita-Salute San Raffaele University (UniSR) and Functional Unit Head at San Raffaele Hospital (OSR) , Milan, Italy. Her research focuses on neuroimaging in neurodegenerative diseases , including Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS). PhD in Experimental Neurology (2012), UniSR Neurology Qualification (2008), UniSR MD in Medicine and Surgery (2003), UniSR Research Interests : Federica Agosta's work bridges functional MRI (fMRI) with clinical applications in neurodegenerative disorders. She investigates: Brain network alterations in Alzheimer's and Parkinson's Neuroimaging biomarkers for ALS and dementia Gender-specific neurological manifestations Advanced MRI techniques for early disease detection Cognitive rehabilitation strategies Neurodegeneration and brain connectivity Recent Publications highlight trends in neuroimaging endpoints for ALS, memory systems, Parkinson's scales, sleep apnea, and epilepsy diagnostics. Her ERC Starting Grant (2017) and European Grand Prix for Young Researcher (2019) underscore her leadership in neurodegenerative disease research. Scientific Roles : Coordinator, Doctoral Program in Cognitive and Behavioral Sciences (UniSR, 2024–) Co-PI, San Raffaele Neurotech Hub (2024–) President, Master's Degree Council in Rehabilitation Sciences (2021–) Visiting Professor, University of Belgrade (2017–) Editorial & Societal Contributions : Member of the EAN Scientific Committee , Co-Chair of the ALS & FTD Panel , and active roles in societies like SIN and SINdem . She serves on editorial boards for Neurological Sciences and Neurology .
